N-Acetylcysteine and Smoking Reduction
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
N-acetylcysteine is an inexpensive agent with a benign side effect profile with preliminary studies in humans suggesting efficacy for the treatment of cocaine dependence. N-acetylcysteine has been used in clinical medicine for nearly three decades to treat chronic lung conditions, acetaminophen overdose, and experimentally to treat cocaine dependence. It is generally safe and well tolerated. The present pilot study seeks to explore safety and tolerability, ad lib smoking, visual cue reactivity, and smoking reduction rates in a group of nontreatment seeking, nicotine dependence smokers who are willing to undergo a brief trial with oral N-acetylcysteine 1200 mg twice daily.
| Condition | Intervention | Phase |
|---|---|---|
|
Nicotine Dependence |
Drug: N-acetylcysteine Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized Controlled Trial of Oral N-acetylcysteine for Smoking Reduction: a Pilot Study |
- Carbon Monoxide Levels [ Time Frame: Weekly ] [ Designated as safety issue: No ]
- Smoking Level [ Time Frame: Weekly ] [ Designated as safety issue: No ]
- Craving Levels (Questionnaire for Smoking Urges -- Brief) [ Time Frame: Weekly ] [ Designated as safety issue: No ]
- Minnesota Nicotine Withdrawal Scale (MNWS) [ Time Frame: Weekly ] [ Designated as safety issue: No ]
- Smoking Level [ Time Frame: Daily ] [ Designated as safety issue: No ]
| Enrollment: | 33 |
| Study Start Date: | December 2006 |
| Study Completion Date: | October 2007 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
2400mg N-acetylcysteine (1200mg b.i.d.) for 4 consecutive weeks
|
Drug: N-acetylcysteine
2400mg (1200mg b.i.d., 600mg capsules, p.o.)
|
|
Placebo Comparator: 2
Identically appearing placebo pills, packaged in an N-acetylcysteine "slurry" so that placebo will retain smell similar to active NAC capsules
|
Drug: Placebo
Identically appearing placebo capsules, packaged in an N-acetylcysteine "slurry" so that placebo has similar odor as active NAC capsules
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Be smokers motivated to reduce their cigarette usage but not seeking treatment to quit smoking at the time of screening.
- Be Able to give written informed consent after being presented with an IRB-approved informed consent document
- Be male or female of any race, between eighteen and sixty five years of age.
- Be in stable physical and mental health as judged by interview
- Be smoking 10 or more cigarettes per day for one or more years
- Have an expired CO reading of ≥10 parts/million prior to beginning study
- Test non-pregnant and use adequate birth control (female only). All female subjects will have a urine pregnancy test performed prior to the first dose of study medication.
- Be able to comply with protocol requirements and be likely to complete all study treatments.
- Live within 50 miles of the study site
Exclusion Criteria:
- Have current dependence, defined by DSM IV criteria, on any psychoactive substance other than nicotine, alcohol, or marijuana or physiological dependence on alcohol requiring medical detoxification.
- Have a history of significant hepatic, renal, endocrine, cardiac (i.e., arrhythmia requiring medication, angina pectoris, myocardial infarction,), stroke, seizure, neurological, non-drug-related psychiatric, gastrointestinal, pulmonary, hematologic or metabolic disorders.
- Have a history of adverse reaction/hypersensitivity to N-acetylcysteine.
- Have any significant active medical or psychiatric illness (e.g. schizophrenia, suicidal/homicidal ideation within the past 30 days) which might inhibit their ability to complete the study or might be complicated by administration of NAC.
- Used carbamazepine or Nitroglycerin within the last 14 days or any other medication felt to be hazardous if taken with NAC
- Have a current or past history of asthma and/or the occasional or daily use of Albuterol or other beta-agonist inhalers.
- Females pregnant or breast-feeding
- Have any medical history or condition considered by the investigator(s) to place the subjects at increased risk.
- Not fail to actively meet the inclusion criteria at the time of screening.
- Have a history of childhood or adult seizures of any cause.
- Be currently taking any medications (i.e., beta-blockers, stimulant medications) that might affect heart rate or skin conductance
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Steven D. LaRowe, Ph.D.; Research Assistant Professor, Principal Investigator, Medical Univeristy of South Carolina |
| ClinicalTrials.gov Identifier: | NCT00751257 History of Changes |
| Other Study ID Numbers: | P50 DA015369, P50DA015369 |
| Study First Received: | September 10, 2008 |
| Last Updated: | September 11, 2012 |
| Health Authority: | United States: Food and Drug Administration United States: Federal Government |
Keywords provided by Medical University of South Carolina:
|
Nicotine N-acetylcysteine smoking reduction |
Additional relevant MeSH terms:
|
Tobacco Use Disorder Smoking Substance-Related Disorders Mental Disorders Habits Acetylcysteine N-monoacetylcystine Antiviral Agents Anti-Infective Agents Therapeutic Uses |
Pharmacologic Actions Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes |
ClinicalTrials.gov processed this record on June 13, 2013